A–Z LIBRARYFOCUS
Every peptide in the index
Filter by receptor class or search by name. Each entry links to a full reference page with mechanism, evidence and primary sources.
Weight-loss peptides
Peptides with human or clinical evidence for body-weight or body-fat reduction, with their receptor class and regulatory status. Approved status refers to a licensed indication somewhere — not always an obesity indication.
| PEPTIDE | CLASS | RECEPTORS | STATUS |
|---|---|---|---|
| SemaglutideOzempic · Wegovy · Rybelsus | GLP-1 | GLP-1R | Approved |
| TirzepatideMounjaro · Zepbound | Dual agonist | GIP + GLP-1 | Approved |
| RetatrutideGLP-3 · LY3437943 · reta | GLP-3 | GLP-1 + GIP + glucagon | Phase 3 |
| LiraglutideVictoza · Saxenda | GLP-1 | GLP-1R | Approved |
| SurvodutideBI 456906 | GLP-3 | GLP-1 + glucagon | Phase 3 |
| MazdutideIBI362 · LY3305677 | GLP-3 | GLP-1 + glucagon | Phase 3 |
| CagrilintideAM833 | Amylin | Amylin + calcitonin receptors | Phase 3 |
| OrforglipronLY3502970 | GLP-1 | GLP-1R | Phase 3 |
| EfinopegdutideMK-6024 · HM12525A | GLP-3 | GLP-1 + glucagon | Phase 2 |
| ExenatideByetta · Bydureon · Exendin-4 | GLP-1 | GLP-1R | Approved |
| Oxyntomodulin | Native hormones | GLP-1R + glucagon receptor | Native hormone |
| TesamorelinEgrifta · TH9507 | GH secretagogues | GHRH receptor | Approved |
| AOD-9604hGH fragment 176-191 | Longevity & metabolic | Beta-3 adrenergic-linked lipolytic pathways (proposed) | Research |
Full index
| PEPTIDE | CLASS | RECEPTORS | STATUS |
|---|---|---|---|
| AOD-9604hGH fragment 176-191 | Longevity & metabolic | Beta-3 adrenergic-linked lipolytic pathways (proposed) | Research |
| BPC-157Body Protection Compound 157 · PL 14736 | Repair & recovery | No confirmed single receptor; VEGFR2/nitric-oxide pathway effects reported | Research |
| CagrilintideAM833 | Amylin | Amylin + calcitonin receptors | Phase 3 |
| CJC-1295Modified GRF (1-29) · CJC-1295 with DAC | GH secretagogues | GHRH receptor | Research |
| DulaglutideTrulicity | GLP-1 | GLP-1R | Approved |
| EfinopegdutideMK-6024 · HM12525A | GLP-3 | GLP-1 + glucagon | Phase 2 |
| EpitalonEpithalon · AEDG peptide | Longevity & metabolic | Proposed effects on telomerase expression and pineal function | Research |
| ExenatideByetta · Bydureon · Exendin-4 | GLP-1 | GLP-1R | Approved |
| GHK-CuCopper tripeptide-1 · Glycyl-L-histidyl-L-lysine copper | Repair & recovery | Copper transport / gene-expression modulation | Research |
| GIPGlucose-dependent insulinotropic polypeptide | Native hormones | GIPR | Native hormone |
| Glepaglutide | GLP-2 | GLP-2R | Phase 3 |
| GLP-1Glucagon-like peptide-1 · Proglucagon 78–108 | Native hormones | GLP-1R | Native hormone |
| HexarelinExamorelin | GH secretagogues | GHS-R1a and CD36 | Research |
| IGF-1 LR3Long R3 insulin-like growth factor-1 | GH secretagogues | IGF-1 receptor | Research |
| IpamorelinNNC 26-0161 | GH secretagogues | Ghrelin receptor (GHS-R1a) | Research |
| KPVLysine-proline-valine · α-MSH (11-13) | Immune & inflammation | Intracellular anti-inflammatory signalling; melanocortin-derived | Research |
| LiraglutideVictoza · Saxenda | GLP-1 | GLP-1R | Approved |
| MazdutideIBI362 · LY3305677 | GLP-3 | GLP-1 + glucagon | Phase 3 |
| Melanotan IIMT-2 | Melanocortin | Non-selective melanocortin agonist (MC1R, MC3R, MC4R, MC5R) | Research |
| MOTS-cMitochondrial ORF of the 12S rRNA type-c | Longevity & metabolic | AMPK activation; nuclear translocation under stress | Research |
| OrforglipronLY3502970 | GLP-1 | GLP-1R | Phase 3 |
| Oxyntomodulin | Native hormones | GLP-1R + glucagon receptor | Native hormone |
| PT-141Bremelanotide · Vyleesi | Melanocortin | Melanocortin receptors (primarily MC4R) | Approved |
| RetatrutideGLP-3 · LY3437943 · reta | GLP-3 | GLP-1 + GIP + glucagon | Phase 3 |
| SelankTuftsin analogue TP-7 | Neuro & cognitive | GABAergic and enkephalin-pathway modulation | Research |
| SemaglutideOzempic · Wegovy · Rybelsus | GLP-1 | GLP-1R | Approved |
| SemaxACTH (4-10) analogue | Neuro & cognitive | BDNF/NGF modulation; melanocortin-derived sequence | Research |
| SermorelinGRF (1-29) · Geref | GH secretagogues | GHRH receptor | Approved |
| SurvodutideBI 456906 | GLP-3 | GLP-1 + glucagon | Phase 3 |
| TB-500Thymosin beta-4 fragment · Tβ4 | Repair & recovery | Actin-binding; no classical receptor | Research |
| TeduglutideGattex · Revestive | GLP-2 | GLP-2R | Approved |
| TesamorelinEgrifta · TH9507 | GH secretagogues | GHRH receptor | Approved |
| Thymosin alpha-1Tα1 · Zadaxin · Thymalfasin | Immune & inflammation | Toll-like receptors (TLR2/TLR9) on immune cells | Approved |
| TirzepatideMounjaro · Zepbound | Dual agonist | GIP + GLP-1 | Approved |